Sagent Pharmaceuticals 401(k) match, vesting and fees

Plan year 2024 filingSagent Pharmaceuticals Inc 401k Plan · Plan 001 · EIN 20-5522946Updated Oct 2026

What Sagent Pharmaceuticals' 401(k) plan says about matching contributions

The match terms have not been published from this plan's filing yet.
The plan year 2024 filing reports $536K in employer contributions, about $2,302 per participant. That total includes any match and profit-sharing; it is not a match formula. Plan year 2024 Form 5500 ↗
$129,380
Average account balance
241
Participants (end of year)
$30.1M
Plan assets (end of year)
0.23%
Admin expenses ÷ assets

Plan features

Match, vesting and enrollment details have not been published from this plan's audit report yet. The figures below come from the structured filing.

RecordkeeperSageview Advisory Group LLCSchedule C ↗
Independent auditorCutrara & Company (unmodified opinion, limited scope)Schedule H ↗
Plan type and status401(k) · ActiveForm 5500 ↗

How the plan compares

Plan year 2024 medians for 8,908 defined-contribution plans in manufacturing with 100 to 499 participants.

Sagent Pharmaceuticals: employer contribution per participant$2,302
Peer median$1,847
Sagent Pharmaceuticals: average balance$129,380
Peer median$65,512
Sagent Pharmaceuticals: admin expenses ÷ assets0.23%
Peer median0.32%

Admin expenses are the plan's reported administrative expenses divided by its assets; they do not include fund expense ratios.

Plan history

Plan assets went from $30.1M at the end of plan year 2021 to $30.1M at the end of plan year 2024.

$30.1M2021$24.3M2022$27.9M2023$30.1M2024
End-of-year figures from each plan year's Form 5500 filing for the Sagent Pharmaceuticals plan.
Plan yearParticipantsAssetsEmployer contributionsPer participantAdmin expense ratioMatch formulaFiling
2024241$30.1M$536K$2,3020.23%Not publishedForm 5500 ↗
2023273$27.9M$745K$2,8120.12%Not publishedForm 5500 ↗
2022371$24.3M$761K$2,1750.27%Not publishedForm 5500 ↗
2021375$30.1M$866K$2,4390.23%Not publishedForm 5500 ↗

Other Sagent Pharmaceuticals plans (1)

Each plan files its own Form 5500. Figures are from each plan's latest filing.

Sagent Pharmaceuticals, Inc. Pr 401(k) Plan

Plan 002 · EIN 20-5522946 · plan year 2025 filing · terminated
—
Average account balance
0
Participants (end of year)
$0
Plan assets (end of year)
0.11%
Admin expenses ÷ assets

Plan features

Match, vesting and enrollment details have not been published from this plan's audit report yet. The figures below come from the structured filing.

Plan type and statusProfit-sharing · Terminated (final filing)Form 5500 ↗

Common questions

Does Sagent Pharmaceuticals match 401(k) contributions?

The match terms for the Sagent Pharmaceuticals Inc 401k Plan have not been published from its filing yet. The plan year 2024 filing reports $536K in employer contributions, about $2,302 per participant. That total includes any match and profit-sharing; it is not a match formula.

When is the Sagent Pharmaceuticals 401(k) match vested?

The vesting schedule for the Sagent Pharmaceuticals Inc 401k Plan is not in the data published so far. Your Summary Plan Description states it.

Who manages the Sagent Pharmaceuticals 401(k)?

The recordkeeper listed on Schedule C of the plan year 2024 filing is Sageview Advisory Group LLC. The plan administrator is Sagent Pharmaceuticals Inc.

I left Sagent Pharmaceuticals. How do I find my old 401(k)?

Your account stays in the plan until you move it. Contact the plan administrator (Sagent Pharmaceuticals Inc, (847) 908-1661) or the recordkeeper, Sageview Advisory Group LLC. The Sagent Pharmaceuticals old 401(k) page lists the contacts from every plan filing. Find an old Sagent Pharmaceuticals 401(k)

Data from the public Form 5500 annual reports Sagent Pharmaceuticals filed with the U.S. Department of Labor (plan years 2021 and 2022 and 2023 and 2024 and 2025) and, where noted, the attached independent auditor's report. Plan terms may have changed since the filing; check your current Summary Plan Description. PlanFacts is not affiliated with Sagent Pharmaceuticals. Not financial advice. Report a correction · Methodology